Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 6,602 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Meningococcal Meningitis
Interventions: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 37 Months to 63 Months
Enrollment: 433 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 19
States / cities: Birmingham, Alabama • Downey, California • Oakland, California + 15 more

Conditions: Age Related Maculopathy, Retinal Degeneration
Interventions: Module 1: Visual Awareness and Eccentric Viewing, Module 2: Control of Reading Eye Movements, Module 3: Reading Practice with RSVP; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Bardet-Biedl Syndrome
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Not listed
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Osteoarthritis, Knee
Interventions: Cingal, Triamcinolone Hexacetonide (TH), Placebo; Drug
Lead sponsor: Anika Therapeutics, Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 26
States / cities: Chandler, Arizona • Tucson, Arizona • Anaheim, California + 21 more

Conditions: Barrett Esophagus
Interventions: CryoBalloon Ablation System; Device
Lead sponsor: Pentax Medical; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 11
States / cities: Orange, California • Sarasota, Florida • Chicago, Illinois + 8 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Bexagliflozin tablets, Bexagliflozin tablets, placebo; Drug
Lead sponsor: Theracos; Industry
Eligibility: 20 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 32
States / cities: Peoria, Arizona • Tucson, Arizona • Canoga Park, California + 29 more

Conditions: Non-Small Cell Lung Cancer
Interventions: ASA404, Placebo, carboplatin, Paclitaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 100
States / cities: Mobile, Alabama • Tucson, Arizona • Bentonville, Arkansas + 86 more

Conditions: SARS-CoV-2 Infection
Interventions: Convalescent Plasma (anti-SARS-CoV-2 plasma), Non-convalescent Plasma (control plasma); Biological
Lead sponsor: Max O'Donnell; Other
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Peripheral Artery Disease
Interventions: Intravascular Lithotripsy; Device
Lead sponsor: Shockwave Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 39
States / cities: Fresno, California • La Jolla, California • Los Angeles, California + 33 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Dexpramipexole, Placebo; Drug
Lead sponsor: Knopp Biosciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 942 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 43
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 39 more

Conditions: Cardiac Resynchronization Therapy
Interventions: Bi-ventricular lead placement; Device
Lead sponsor: Stereotaxis; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 6
States / cities: Gainesville, Georgia • Lexington, Kentucky • Boston, Massachusetts + 3 more

Conditions: Graft Occlusion, Vascular, Coronary Restenosis, Atherosclerosis
Interventions: BO-653; Drug
Lead sponsor: Chugai Pharma USA; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 29
States / cities: Phoenix, Arizona • Tucson, Arizona • Burlingame, California + 24 more

Conditions: Cellular Diagnosis, Prostate Cancer
Interventions: ClariCore System; Device
Lead sponsor: Precision Biopsy, Inc.; Industry
Eligibility: 22 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 5
States / cities: Denver, Colorado • Baltimore, Maryland • Royal Oak, Michigan + 2 more

Conditions: Triple Negative Breast Cancer, Inflammatory Breast Cancer Stage IV
Interventions: Bemcentinib; pembrolizumab; Drug
Lead sponsor: BerGenBio ASA; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Duarte, California • San Diego, California • Kansas City, Missouri + 2 more

Conditions: Bladder Disease
Interventions: Bladder biopsy; Procedure
Lead sponsor: Tengion; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Sacroiliac Joint Disruption, Degenerative Sacroiliitis
Interventions: CATAMARAN SI Joint Fusion System; Device
Lead sponsor: Tenon Medical; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Coeur d'Alene, Idaho • Muncie, Indiana • Louisville, Kentucky + 3 more

Conditions: Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma, Solid Tumor, Unspecified, Adult, Tumor, Solid
Interventions: INV-1120, Pembrolizumab; Drug · Combination Product
Lead sponsor: Shenzhen Ionova Life Sciences Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Lafayette, Indiana • San Antonio, Texas

Conditions: Rheumatoid Arthritis
Interventions: Fostamatinib, Adalimumab, Placebo of Fostamatinib, Placebo of Adalimumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Glendale, Arizona • Paradise Valley, Arizona • Phoenix, Arizona + 3 more

Conditions: Healthy Subjects
Interventions: E5555; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Primary Sclerosing Cholangitis
Interventions: Vancomycin, Placebo; Drug · Other
Lead sponsor: Elizabeth Carey; Other
Eligibility: 18 Years to 76 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Phoenix, Arizona • Tempe, Arizona • Jacksonville, Florida + 1 more

Conditions: Advanced Solid Tumors Cancer
Interventions: ABBV-428, Nivolumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 7
States / cities: Scottsdale, Arizona • Sacramento, California • Chicago, Illinois + 4 more

Conditions: Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human, Liver Cirrhosis
Interventions: Civacir® 10%; Biological
Lead sponsor: Biotest Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 23
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 15 more

Conditions: Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma Refractory, Multiple Myeloma in Relapse
Interventions: EZM0414; Drug
Lead sponsor: Epizyme, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 8
States / cities: Duarte, California • East Brunswick, New Jersey • New York, New York + 3 more

Conditions: Electronic Cigarette Use, Cigarette Use, Electronic, Tobacco Use, Tobacco Smoking
Interventions: JUUL ENDS 5% Virginia Tobacco, JUUL 3% Virginia Tobacco ENDS, JUUL 5% Mint ENDS, JUUL 3% Mint ENDS, JUUL 5% Menthol ENDS, JUUL 3% Menthol ENDS, JUUL 5% Mango ENDS, JUUL 3% Mango ENDS, US Cigarette, Non-menthol - Marlboro Gold King Size, US Cigarette, Menthol - Newport King Size; Other
Lead sponsor: Juul Labs, Inc.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 3
States / cities: Secaucus, New Jersey • Charlotte, North Carolina • Raleigh, North Carolina

Search by objective public record fields.

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

A Multi-Center Study of Reading Rehabilitation in Macular Disease

Genetics and Clinical Characteristics of Bardet-Biedl Syndrome

Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain

Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System

A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus

ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer

Plasma Therapy of COVID-19 in Severely Ill Patients

Disrupt PAD BTK II Study With the Shockwave Peripheral IVL System

Phase 3 Study of Dexpramipexole in ALS

MAGNET CRT Feasibility - Efficiency of LV Lead Placement Comparing Conventional vs. Magnetic Guidance

A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.

ClariCore Optical Biopsy System Used in TRUS (Trans-Rectal Ultrasound)-Guided Prostrate Biopsy

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Multi Center Study to Obtain Bladder Tissue Specimens From Patients Undergoing Transurethral Resection Biopsy Procedure

Post-Market Feasibility Study of the Tenon Medical CATAMARAN™ SI Joint Fusion System

An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study

Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 Activity

Vancomycin for Primary Sclerosing Cholangitis

A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

Evaluating Selected Constituents in the Exhaled Breath Samples